Aclaris Therapeutics Announces Issuance of Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders
September 05 2017 - 8:00AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led
biopharmaceutical company focused on identifying, developing and
commercializing innovative and differentiated therapies to address
significant unmet needs in medical and aesthetic dermatology, today
announced that the United States Patent and Trademark Office
(USPTO) has issued U.S. Patent No. 9,737,469 and U.S. Patent No.
9,730,877, which are directed to methods related to the use and
administration of certain janus kinase (JAK) inhibitors for
treating hair loss disorders.
U.S. Patent No. 9,730,877 covers the use of various JAK
inhibitors, including tofacitinib, baricitinib, ruxolitinib and
decernotinib, to treat androgenetic alopecia, also known as
male/female pattern hair loss. Experienced by 70% of men and 40% of
women at some point in their lives, androgenetic alopecia is a
genetic disorder and the most common cause of hair loss. The ‘877
Patent contains 22 claims and expires in November 2031.
U.S. Patent No. 9,737,469 covers the use of baricitinib for
inducing hair growth and for treating hair loss disorders such as
alopecia areata and androgenetic alopecia. Additional issued
claims pertain to methods of using baricitinib to treat particular
phenotypes of alopecia areata, as well as to treat other hair loss
disorders. The ‘469 Patent contains 10 claims and expires in
November 2031.
These newly allowed patents are owned by The Trustees of
Columbia University in the City of New York and exclusively
licensed to Aclaris, and are the latest U.S. patents to issue in
connection with Aclaris' JAK drug development program for
hair loss disorders.
“We are extremely pleased with the continued development of the
patent portfolio we exclusively licensed from Columbia. These
new issuances continue to expand the breadth and depth of our JAK
inhibitor intellectual property portfolio covering methods of use
for certain JAK inhibitors for the treatment of hair loss
disorders. The issuance of these patents is another successful step
in the development of a robust patent portfolio relating to JAK
inhibition and hair loss,” said Dr. Neal Walker, President and
Chief Executive Officer of Aclaris.
Aclaris has exclusively licensed several patents and patent
applications involving novel selective JAK 1/3 inhibitors,
including a patent portfolio from Rigel Pharmaceuticals, Inc. that
covers Aclaris’ product candidates ATI-50001 and ATI-50002, which
are oral and topical formulations, respectively, also being
developed as potential treatments for alopecia areata.
Additionally, Aclaris has exclusively licensed a patent portfolio
from Columbia University directed to methods of using JAK
inhibitors for the treatment of alopecia areata, androgenetic
alopecia, and other dermatological conditions. This portfolio
includes the recently issued U.S. patents discussed above, as well
as an issued U.S. patent directed to methods of treating alopecia
areata, androgenetic alopecia and other hair loss disorders by
administering ruxolitinib and issued patent claims in Japan
directed to pharmaceutical compositions comprising ruxolitinib,
baricitinib or other JAK inhibitors for use in treating alopecia
areata, androgenetic alopecia and other hair loss disorders.
About Aclaris Therapeutics, Inc.Aclaris
Therapeutics, Inc. is a dermatologist-led biopharmaceutical company
focused on identifying, developing and commercializing innovative
and differentiated therapies to address significant unmet needs in
medical and aesthetic dermatology. Aclaris is focused on
large, underserved market segments with no FDA-approved medications
or where treatment gaps exist. Aclaris is based in Malvern,
Pennsylvania and more information can be found by visiting the
Aclaris website at www.aclaristx.com.
Cautionary Note Regarding Forward-Looking
Statements Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements may be
identified by words such as “believe”, “expect”, “may”, “plan,”
“potential,” “will,” and similar expressions, and are based on
Aclaris’ current beliefs and expectations. These forward-looking
statements include expectations regarding the development of
Aclaris’ product candidates focused on JAK inhibition for the
treatment of hair loss disorders, including Aclaris’ intellectual
property strategy. These statements involve risks and uncertainties
that could cause actual results to differ materially from those
reflected in such statements. Risks and uncertainties that may
cause actual results to differ materially include uncertainties
inherent in the conduct of clinical trials, Aclaris’ reliance on
third parties over which it may not always have full control, risks
associated with maintaining its intellectual property portfolio and
other risks and uncertainties that are described in Aclaris’ Annual
Report on Form 10-K for the year ended December 31, 2016, Aclaris’
Quarterly Report on Form 10-Q for the quarter ended June 30, 2017,
and other filings Aclaris makes with the SEC from time to time.
These documents are available under the “Financial Information”
section of the Investors page of Aclaris’ website at
http://www.aclaristx.com. Any forward-looking statements speak only
as of the date of this press release and are based on information
available to Aclaris as of the date of this release, and Aclaris
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
Aclaris Contact
Michael Tung, M.D.
Investor Relations
484-329-2140
mtung@aclaristx.com
Media Contact
Mariann Caprino
TogoRun
917-242-1087
M.Caprino@togorun.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024